Literature DB >> 17659565

Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts.

Omar Cauli1, Regina Rodrigo, Blanca Piedrafita, Jordi Boix, Vicente Felipo.   

Abstract

UNLABELLED: One of the neurological alterations in patients with minimal or overt hepatic encephalopathy is cognitive impairment. This impairment is reproduced in rats with chronic liver failure due to portacaval shunt (PCS). These rats show decreased ability to learn a conditional discrimination task in a Y-maze, likely due to reduced function of the glutamate-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway in brain. It has been proposed that inflammation exacerbates the neuropsychological alterations induced by hyperammonemia, suggesting that inflammation-associated alterations may contribute to cognitive impairment in hepatic encephalopathy. This study assessed whether treatment with an anti-inflammatory drug, ibuprofen, is able to restore the function of the glutamate-NO-cGMP pathway in cerebral cortex in brain in vivo and/or learning ability in PCS rats. We show that PCS rats have increased levels of interleukin-6 and increased activities of cyclooxygenase and of inducible NO synthase in cerebral cortex, indicating the presence of inflammation. Chronic treatment with ibuprofen normalizes cyclooxygenase and inducible NO synthase activities but not interleukin-6 levels. Moreover, ibuprofen normalizes the function of the glutamate-NO-cGMP pathway in cerebral cortex in vivo and completely restores the ability of rats with chronic liver failure to learn the Y-maze task. This supports that inflammation contributes to the cognitive impairment in hepatic encephalopathy.
CONCLUSION: the results reported point to the possible therapeutic utility of decreasing inflammation in the treatment of the cognitive deficits in patients with minimal or overt hepatic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17659565     DOI: 10.1002/hep.21734

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  61 in total

1.  Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.

Authors:  Vicente Felipo; Amparo Urios; Encarna Montesinos; Inmaculada Molina; Maria L Garcia-Torres; Miguel Civera; Juan A Del Olmo; Joaquin Ortega; Jose Martinez-Valls; Miguel A Serra; Norberto Cassinello; Abdallah Wassel; Esperanza Jordá; Carmina Montoliu
Journal:  Metab Brain Dis       Date:  2011-11-10       Impact factor: 3.584

Review 2.  Changing face of hepatic encephalopathy: role of inflammation and oxidative stress.

Authors:  Amit S Seyan; Robin D Hughes; Debbie L Shawcross
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

Review 3.  Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.

Authors:  Ming Luo; Jian-Yang Guo; Wu-Kui Cao
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

4.  Hippocampal atrophy and functional connectivity disruption in cirrhotic patients with minimal hepatic encephalopathy.

Authors:  Weiwen Lin; Xuhui Chen; Yong-Qing Gao; Zhe-Ting Yang; Weizhu Yang; Hua-Jun Chen
Journal:  Metab Brain Dis       Date:  2019-07-30       Impact factor: 3.584

5.  Is there a direct role of hepatitis C virus in portosystemic encephalopathy?

Authors:  Giovanni Tarantino
Journal:  J Gastroenterol       Date:  2008-03-29       Impact factor: 7.527

Review 6.  Brain edema: a valid endpoint for measuring hepatic encephalopathy?

Authors:  Chantal Bémeur; Cristina Cudalbu; Gitte Dam; Alexander S Thrane; Arthur J L Cooper; Christopher F Rose
Journal:  Metab Brain Dis       Date:  2016-06-07       Impact factor: 3.584

Review 7.  Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation.

Authors:  Dominic R Aldridge; Edward J Tranah; Debbie L Shawcross
Journal:  J Clin Exp Hepatol       Date:  2014-06-30

Review 8.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 9.  Systemic inflammation and ammonia in hepatic encephalopathy.

Authors:  Thomas H Tranah; Godhev K Manakkat Vijay; Jennifer M Ryan; Debbie L Shawcross
Journal:  Metab Brain Dis       Date:  2012-12-07       Impact factor: 3.584

10.  Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis.

Authors:  Jayanta Samanta; Radha K Dhiman; Amit Khatri; Kiran K Thumburu; Sandeep Grover; Ajay Duseja; Yogesh Chawla
Journal:  Metab Brain Dis       Date:  2013-03-15       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.